Cardurion Pharmaceuticals
Cardurion Pharmaceuticals is a cardiovascular drug developer that raised $603M, including a $300M investment from Bain Capital in July 2024. The company focuses on PDE9 and CaMKII inhibition therapies for heart failure and other cardiovascular diseases.
The growth story
Cardurion Pharmaceuticals grew from 14 to 74 employees between 2021 and 2026, raising $603M along the way, most recently a Series B in July 2024.
About
Cardurion develops novel therapeutics for cardiovascular diseases, with a focus on PDE9 and CaMKII inhibition. The company uses in-house drug discovery and strategic partnerships to advance its clinical programs.
The company has raised $603M, including a $300M investment from Bain Capital in July 2024. Its Series B funding supports current programs and pipeline growth, positioning Cardurion as a significant player in cardiovascular drug development.
Founders and leadership
Cardurion is led by a team of cardiovascular experts and industry veterans. The largest function is Operations, with 9 employees. The company has a median tenure of 2 years, indicating a relatively stable workforce.
The Cardurion Pharmaceuticals org chart
Peter Lawrence (CEO and President) leads 57 mapped leaders with 5 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 14 (-18% YoY), Operations 11 (0% YoY), Business Development 10 (+11% YoY), Healthcare Services 6 (0% YoY), Program and Project Management 6 (-25% YoY), Finance 4 (0% YoY).
Talent flow
Cardurion's team primarily comes from major pharmaceutical companies, including Takeda, Bristol Myers Squibb, and Biogen. Alumni have moved to roles at MBX Biosciences, Beren Therapeutics, and Ascenta Capital.
Most common previous employers of Cardurion Pharmaceuticals staff: Takeda (10), Bristol Myers Squibb (8), Biogen (6), ArQule (5), Sanofi (4), Affinivax (4). Former Cardurion Pharmaceuticals employees most often moved to MBX Biosciences (1), Harvard Kennedy School (1), Port City Labs (1), Ascenta Capital (1), Beren Therapeutics (1), Summit Regulatory Consulting (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at Cardurion Pharmaceuticals: Pharmaceutics (28), Clinical Trials (27), Biotechnology (22), Clinical Development (21), Clinical Research (21), Good Clinical Practice (GCP) (20), Drug Development (20), Leadership (17).
Where the team actually sits
Cardurion Pharmaceuticals people are concentrated in Massachusetts, United States (25), Greater Boston (11), United States (6), New Jersey, United States (3).
Search footprint
Cardurion Pharmaceuticals attracts about 131 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 14 ranking keywords and lost 11 in the last period.
What employees say
- Compensation
- 4.00 / 5
- Career opportunities
- 4.00 / 5
- Senior management
- 4.00 / 5
- Work-life balance
- 3.00 / 5
Frequently asked
Cardurion Pharmaceuticals has 74 employees as of September 2026.
Cardurion Pharmaceuticals has raised $603M in total, most recently a Series B round in July 2024.
Peter Lawrence (CEO and President) sits at the top of Cardurion Pharmaceuticals's reporting structure, with 5 direct reports.
The most common previous employers of current Cardurion Pharmaceuticals staff are Takeda (10 people), Bristol Myers Squibb (8 people), Biogen (6 people).
Former Cardurion Pharmaceuticals employees most often move to MBX Biosciences (1), Harvard Kennedy School (1), Port City Labs (1).
Cardurion Pharmaceuticals attracts about 131 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among Cardurion Pharmaceuticals staff are Pharmaceutics, Clinical Trials, Biotechnology, Clinical Development, Clinical Research.
Cardurion Pharmaceuticals staff are concentrated in Massachusetts, United States (25), Greater Boston (11), United States (6).
Cardurion Pharmaceuticals has about 14 people in Research, down 18% over the past year, as of September 2026.
Cardurion Pharmaceuticals has about 11 people in Operations, up 0% over the past year, as of September 2026.
Computed from 67 current and 31 former Cardurion Pharmaceuticals profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.